CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
Globenewswire·2025-06-24 17:00
Press release CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause Dijon, France June 24, 2025 (7.00 PM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company in late-stage clinical and regulatory development of ZEPIZURE®, its emergency treatment for the management of epileptic seizures based on the award-winning ZENEO® needle-free auto- injector, announces the successful completion of its capital increase wit ...